1. Home
  2. CRBP vs CMCM Comparison

CRBP vs CMCM Comparison

Compare CRBP & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • CMCM
  • Stock Information
  • Founded
  • CRBP 2009
  • CMCM 2009
  • Country
  • CRBP United States
  • CMCM China
  • Employees
  • CRBP N/A
  • CMCM N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • CRBP Health Care
  • CMCM Technology
  • Exchange
  • CRBP Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • CRBP 110.3M
  • CMCM 115.1M
  • IPO Year
  • CRBP N/A
  • CMCM 2014
  • Fundamental
  • Price
  • CRBP $8.90
  • CMCM $4.85
  • Analyst Decision
  • CRBP Strong Buy
  • CMCM
  • Analyst Count
  • CRBP 10
  • CMCM 0
  • Target Price
  • CRBP $53.56
  • CMCM N/A
  • AVG Volume (30 Days)
  • CRBP 124.3K
  • CMCM 56.3K
  • Earning Date
  • CRBP 08-05-2025
  • CMCM 09-12-2025
  • Dividend Yield
  • CRBP N/A
  • CMCM N/A
  • EPS Growth
  • CRBP N/A
  • CMCM N/A
  • EPS
  • CRBP N/A
  • CMCM N/A
  • Revenue
  • CRBP N/A
  • CMCM $120,663,543.00
  • Revenue This Year
  • CRBP N/A
  • CMCM $14.27
  • Revenue Next Year
  • CRBP $270.04
  • CMCM $39.26
  • P/E Ratio
  • CRBP N/A
  • CMCM N/A
  • Revenue Growth
  • CRBP N/A
  • CMCM 27.02
  • 52 Week Low
  • CRBP $4.64
  • CMCM $3.02
  • 52 Week High
  • CRBP $61.89
  • CMCM $6.77
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 53.56
  • CMCM 44.38
  • Support Level
  • CRBP $9.10
  • CMCM $4.69
  • Resistance Level
  • CRBP $9.80
  • CMCM $6.62
  • Average True Range (ATR)
  • CRBP 0.62
  • CMCM 0.45
  • MACD
  • CRBP 0.01
  • CMCM -0.14
  • Stochastic Oscillator
  • CRBP 31.45
  • CMCM 8.29

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: